pipette., The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed clinical trials

A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at two different Concentrations in patients with Dry Eye Disease (REDUCO study)

This study is testing a new eye drop for dry eye disease. It uses a man-made version of a natural body substance to see if it improves dry eye symptoms and overall eye health over 8 weeks, with a follow-up period.